SEARCH

SEARCH BY CITATION

References

  • Bandarenko, N. & Brecher, M.E. (1998) United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. Journal of Clinical Apheresis, 13, 133141.
  • Bell, W.R., Braine, H.G., Ness, P.M. & Kickler, T.S. (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. New England Journal of Medicine, 325, 398403.
  • Bobbio-Pallavicini, E., Porta, C., Fornasari, P.M., Viarengo, G. & Ascari, E. (1992) Thrombotic thrombocytopenic purpura (TTP): retrospective study of 84 patients and therapeutic prospects. Transfusion Science, 13, 3944.
  • Bobbio-Pallavicini, E., Gugliotta, L., Centurioni, R., Porta, C., Vianelli, N., Billio, A., Tacconi, F. & Ascari, E. (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica, 82, 429435.
  • Brunskill, S.J., Tusold, A., Benjamin, S., Stanworth, S.J. & Murphy, M.F. (2007) A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfusion Medicine, 17, 1735.
  • Colflesh, C.R., Agarwal, R. & Knochel, J.P. (1996) Timing of plasma exchange therapy for thrombotic thrombocytopenia purpura: a brief clinical observation. The American Journal of the Medical Sciences, 311, 167168.
  • Dervenoulas, J., Tsirigotis, P., Bollas, G., Pappa, V., Xiros, N., Economopoulos, T., Pappa, M., Mellou, S., Kostourou, A., Papageorgiou, E. & Raptis, S.A. (2000) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Annals of Hematology, 79, 6672.
  • Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C. & Vandenbroucke, J.P. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 370, 14531457.
  • Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 15781584.
  • George, J.N. (2006) Clinical practice. Thrombotic thrombocytopenic purpura. New England Journal of Medicine, 354, 19271935.
  • George, J.N., Vesely, S.K. & Terrell, D.R. (2004) The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Seminars in Hematology, 41, 6067.
  • Gurkan, E., Baslamisli, F., Guvenc, B., Kilic, N.B., Unsal, C. & Karakoc, E. (2005) Thrombotic thrombocytopenic purpura in southern Turkey: a single-center experience of 29 cases. Clinical and Laboratory Haematology, 27, 121125.
  • Hanley, J.A. & Lippman-Hand, A. (1983) If nothing goes wrong, is everything all right? Interpreting zero numerators Journal of the American Medical Association, 249, 17431745.
  • Hosler, G.A., Cusumano, A.M. & Hutchins, G.M. (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Archives of Pathology & Laboratory Medicine, 127, 834839.
  • Lammle, B., Kremer Hovinga, J.A. & Alberio, L. (2005) Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 3, 16631675.
  • Mintz, P.D., Neff, A., MacKenzie, M., Goodnough, L.T., Hillyer, C., Kessler, C., McCrae, K., Menitove, J.E., Skikne, B.S., Damon, L., Lopez-Plaza, I., Rouault, C., Crookston, K.P., Benjamin, R.J., George, J., Lin, J.S., Corash, L. & Conlan, M.G. (2006) A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion, 46, 16931704.
  • Newcombe, R.G. & Altman, D.G. (2000) Proportions and their differences. In: Statistics with Confidence (eds by D.G.Altman, D.Machin, T.N.Bryant & M.J.Gardner), pp. 4556. BMJ Books, Bristol.
  • Nguyen, L., Li, X., Duvall, D., Terrell, D.R., Vesely, S.K. & George, J.N. (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 48, 349357.
  • Noris, M. & Remuzzi, G. (2005) Hemolytic uremic syndrome. Journal of the American Society of Nephrology, 16, 10351050.
  • Pereira, A., Mazzara, R., Monteagudo, J., Sanz, C., Puig, L., Martinez, A., Ordinas, A. & Castillo, R. (1995) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Annals of Hematology, 70, 319323.
  • Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. & Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 127, 433439.
  • Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. & Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 325, 393397.
  • Rose, M., Rowe, J.M. & Eldor, A. (1993) The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Reviews, 7, 94103.
  • Shamseddine, A., Saliba, T., Aoun, E., Chahal, A., El Saghir, N., Salem, Z., Bazarbachi, A., Khalil, M. & Taher, A. (2004) Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. Journal of Clinical Apheresis, 19, 119124.
  • Shumak, K.H., Rock, G.A. & Nair, R.C. (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Annals of Internal Medicine, 122, 569572.
  • Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 15851594.
  • Vesely, S.K., George, J.N., Lammle, B., Studt, J.D., Alberio, L., El Harake, M.A. & Raskob, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 6068.
  • Veyradier, A. & Girma, J.P. (2004) Assays of ADAMTS-13 activity. Seminars in Hematology, 41, 4147.
  • Wyllie, B.F., Garg, A.X., Macnab, J., Rock, G.A. & Clark, W.F. (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. British Journal of Haematology, 132, 204209.
  • Zeigler, Z.R., Shadduck, R.K., Gryn, J.F., Rintels, P.B., George, J.N., Besa, E.C., Bodensteiner, D., Silver, B. & Kramer, R.E. (2001) Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). Journal of Clinical Apheresis, 16, 1922.